midazolam has been researched along with caffeine in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (3.47) | 18.7374 |
| 1990's | 14 (9.72) | 18.2507 |
| 2000's | 38 (26.39) | 29.6817 |
| 2010's | 66 (45.83) | 24.3611 |
| 2020's | 21 (14.58) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Coassolo, P; Lavé, T; Schneider, G | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Han, G; Ji, C; Jiang, Y; Li, Z; Liu, N; Sheng, C; Tu, J; Wang, Y | 1 |
| Falk, JL; Lau, CE | 2 |
| Spealman, RD | 1 |
| Berti, C; Nistri, A | 2 |
| Cooper, SJ | 1 |
| Fletcher, JE; Hilf, M; Rosenberg, H | 1 |
| Ator, NA; Sannerud, CA | 1 |
| Alastra, AJ; Cohen, C; Goldberg, SR; Marley, RJ; Sannerud, CA; Serdikoff, SL | 1 |
| Kanmura, Y; Yamaguchi, S; Yoshimura, N | 1 |
| Itoh, T; Kanmura, Y; Ohashi, M; Shiraishi, Y; Yamaguchi, S; Yoshimura, N | 1 |
| Beck, DJ; Bertino, JS; Gotschall, R; Kashuba, AD; Kearns, GL; Kulawy, RW; Leeder, JS; Nafziger, AN; Rocci, ML | 1 |
| Agúndez, JA; Albet, C; Benítez, J; Carrillo, JA; Herrero, E; Márquez, M; Martínez, C; Ortiz, JA | 1 |
| Mariathasan, EA; Stolerman, IP; White, JA | 1 |
| Bickel, WK; Smith, BJ | 1 |
| Lewis, IA; Palmer, J; Pleasance, S; Scott, RJ | 1 |
| Bertino, JS; Bleakley, JF; Gaedigk, A; Gotschall, R; Kearns, GL; Kim, JS; Leeder, JS; Nafziger, AN; Streetman, DS | 1 |
| Mattila, MJ; Nurminen, ML; Seppälä, T; Vainio, P; Vanakoski, J | 1 |
| Gorski, JC; Hall, SD; Hamman, MA; Huang, SM; Lesko, LJ; Wang, Z | 1 |
| Dickins, M; Gibson, A; Palmer, JL; Pleasance, S; Scott, RJ | 1 |
| Chen, XP; Huang, SL; Huang, Z; Ou-Yang, DS; Tan, ZR; Zhou, HH | 1 |
| Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y | 1 |
| Aherne, Z; Blakey, GE; Lockton, JA; Norwood, P; Perrett, J; Plume, J; Russell, M | 1 |
| Desai, M; Gorski, JC; Hall, SD; Hamman, MA; Hilligoss, JK; Huang, SM; Miller, M; Pinto, A; Zaheer, NA | 1 |
| Cherkaoui, S; Daali, Y; Dayer, P; Jerdi, MC; Oestreicher, MK | 1 |
| Bartko, M; Baskin, KM; Cahill, AM; Kaye, RD; Rubin, JT; Towbin, RB | 1 |
| Carrier, J; Edwards, DJ; Gardner, SF; Gentry, WB; Gurley, BJ; Hubbard, MA; Khan, IA; Shah, A; Williams, DK | 1 |
| Gardner, SF; Gentry, WB; Gurley, BJ; Hubbard, MA; Khan, IA; Shah, A; Williams, DK | 1 |
| Ang, CY; Cui, Y; Gardner, SF; Gentry, WB; Gurley, BJ; Hubbard, MA; Williams, DK | 1 |
| Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
| Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y | 1 |
| Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH | 1 |
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Johnson, TN; Rostami-Hodjegan, A; Tucker, GT | 1 |
| Cha, IJ; Liu, KH; Ryu, JY; Shin, JG; Shon, JH; Song, IS; Sunwoo, YE | 1 |
| Ashton, M; Asimus, S; Elsherbiny, D; Hai, TN; Huong, NV; Jansson, B; Petzold, MG; Simonsson, US | 1 |
| Cederberg, J; Dahl, ML; Karlsson, MO; Magnusson, MO; Sandström, R | 1 |
| Darwish, M; Hellriegel, ET; Kirby, M; Robertson, P | 1 |
| Karlson-Stiber, C; Schmidt, A | 1 |
| Iqbal, MZ; Lagundoye, O; Lennard, MS; Rostami-Hodjegan, A; Seivewright, N; Shiran, MR; Tucker, GT | 1 |
| Chem, MC; Chetty, M; Ghassabian, S; Glen, J; McLachlan, AJ; Murray, M; Rahme, J; Ramzan, I; Stankovic, Z; Tattam, BN | 1 |
| Cho, JY; Hong, JH; Jang, IJ; Kim, BH; Kim, J; Kim, KP; Lim, KS; Shin, SG; Yi, S; Yu, KS | 1 |
| Ansermot, N; Baumann, P; Crettol, S; Eap, CB; Harenberg, S; Jaquenoud Sirot, E; Knezevic, B; Morena, GP; Oneda, B | 1 |
| Collins, DA; Deng, Y; Jenkins, J; Kitchen, VS; Williams, D | 1 |
| Boulenc, X; Brian, W; Donazzolo, Y; Poitiers, F; Santoni, A; Turpault, S; Van Horn, R | 1 |
| Blake, M; Brown, KC; Gaedigk, A; Gotzkowsky, K; Hein, DW; Jones, AE; Kashuba, AD; van der Horst, C; Werner, RE | 1 |
| Chen, Y; Guo, Y; Klaassen, CD; Tan, ZR; Zhou, HH | 1 |
| Auwärter, V; Dresen, S; Lutz-Bonengel, S; Naue, J; Wohlfarth, A | 1 |
| Guo, C; Han, YL; Jing, GP; Li, D; Li, Y; Meng, XL; Ren, B; Wan, LL; Yu, Q; Zhou, ZY | 1 |
| Desai, D; Grimm, SW; Lin, J; Ribadeneira, MD; Smith, MA; Sunzel, M; Zhou, D | 1 |
| Bekersky, I; Blum, RA; Tolbert, D; Walzer, M | 1 |
| Abduljalil, K; Gaohua, L; Jamei, M; Johnson, TN; Rostami-Hodjegan, A | 1 |
| Doogue, MP; Jensen, BP; Patel, F; Polasek, TM; Sorich, MJ; Wiese, MD | 1 |
| Takayanagi, R; Teramoto, S; Uotsu, N; Yamada, M; Yamada, Y; Yamasaki, I | 1 |
| Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H | 1 |
| Chalasani, N; Hall, SD; Jones, DR; Mattar, S; Tandra, S; Vuppalanchi, R | 1 |
| Jiao, J; Li, Q; Liu, Y; Lou, J; Zhang, C | 1 |
| Fuhr, U; Gerwin, H; Pfeiffer, K; Rokitta, D; Streich, C | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Aarons, L; Johnson, TN; Ogungbenro, K; Rostami-Hodjegan, A; Salem, F; Vajjah, P | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Namiki, N; Tanaka, S; Uchida, S | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Staub, C; Walder, B | 1 |
| Abduljalil, K; Johnson, TN; Rostami-Hodjegan, A; Salem, F; Tucker, GT | 1 |
| Bosilkovska, M; Daali, Y; Dayer, P; Déglon, J; Desmeules, JA; Rebsamen, M; Samer, CF; Staub, C; Walder, B | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Bernstein, HJ; Brinda, BJ; Chavin, KD; Frye, RF; Kawaguchi-Suzuki, M; Markowitz, JS; Zhu, HJ | 1 |
| Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K | 1 |
| Cao, X; Huang, Y; Lan, YY; Li, YJ; Liao, SG; Liu, Y; Lu, Y; Tang, L; Wang, AM; Wang, YL; Zheng, L | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS | 1 |
| Corcoran, M; Ermer, J; Martin, P | 1 |
| Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y | 1 |
| Murayama, N; Shida, S; Shimizu, M; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Berger, B; Derungs, A; Donzelli, M; Haschke, M; Krähenbühl, S; Noppen, C | 1 |
| Bénech, H; Lenuzza, N; Nguyen, TT; Pruvost, A | 1 |
| Hellum, B; Nilsen, OG; Spigset, O; Thu, OK | 1 |
| Kawano, M; Mitsui, M; Sasaki, E; Shimizu, M; Suemizu, H; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Jiang, X; Wang, W; Xu, Z; Zhou, H; Zhuang, Y | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B | 1 |
| Christensen, HR; Dalhoff, KP; Gade, C; Holm, JC; Holst, H; Mikus, G | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA | 1 |
| Mohs, AJ; Peace, MR; Poklis, A; Poklis, JL; Wolf, CE | 1 |
| Jeon, JY; Kim, DS; Kim, MG; Kim, Y | 1 |
| Armani, S; Chun, DY; Darstein, C; Einolf, HJ; Gu, H; Kulkarni, S; Sauter, N; Ting, L; Tripathi, AP; Wang, L; Zhu, B | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN | 1 |
| Berger, PB; Donzelli, M; Früh, M; Gillessen, S; Haschke, M; Joerger, M; Kloft, C; Krähenbühl, S; Parra-Guillen, ZP; Pfister, B; Winogradova, D | 1 |
| Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H | 1 |
| Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA | 1 |
| Gong, Z; Huang, J; Li, Y; Liu, C; Liu, T; Lu, Y; Pan, J; Sun, J; Wang, Y; Zheng, J; Zheng, L | 1 |
| Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D | 1 |
| Jo, JH; Jo, JJ; Kim, S; Lee, JM; Lee, S | 1 |
| Bailey-Smith, C; Bodrug, I; Cheng, A; Glasgow, XS; Hussain, A; Iwamoto, M; Khalilieh, S; Levine, V; Martinho, M; Mekokishvili, L; Montgomery, D; Shaw, PM | 1 |
| Choi, MK; Choi, WG; Han, YH; Heo, JK; Jo, J; Kang, WY; Lee, HS; Lee, HW; Lee, S; Liu, KH; Ohk, B; Seong, SJ; Song, IS; Yoon, YR | 1 |
| Cintra, MACT; Coelho, EB; Cusinato, DAC; Filgueira, GCO; Lanchote, VL; Rocha, A | 1 |
| Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| Chiasson, JL; Grangeon, A; Gravel, S; Michaud, V; Turgeon, J | 1 |
| Hopkins, A; Marshall, JC; Miners, JO; Rowland, A; Sorich, MJ; van Dyk, M; Wood, LS | 1 |
| Enejosa, JV; Feng, T; Fisniku, O; Mohamed, MF; Othman, AA | 1 |
| Abduljalil, K; Jamei, M; Johnson, TN; Pan, X; Pansari, A | 1 |
| Eagles, SK; Gross, AS; McLachlan, AJ; Wang, X | 1 |
| Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y | 1 |
| Chakraborty, A; Dhuria, SV; Elmeliegy, M; He, H; Heimbach, T; Huth, F; Ji, Y; Miller, M; Samant, TS; Schiller, H; Umehara, K | 1 |
| Backman, JT; Isoherranen, N; Kaartinen, TJK; Launiainen, T; Niemi, M; Tapaninen, T; Tornio, A | 1 |
| Ohtsuki, S; Otagiri, M; Sakai, H; Taguchi, K; Tokuno, M; Yamasaki, K | 2 |
| Mohamed, MF; Othman, AA; Sathe, AG | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Kawakami, J; Miura, M; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF | 1 |
| Agarwal, S; Clausen, VA; Harper, P; Najafian, N; Robbie, GJ; Sardh, E; Simon, AR; Vassiliou, D | 1 |
| Ang, DSW; Ang, TL; Benech, H; Koo, SH; Lee, EJD; Pruvost, A; Soon, GH | 1 |
| Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C | 1 |
| Chen, X; Cui, X; Giovannini, M; Isambert, N; Kapoor, S; López-López, R; Mau-Sorensen, M; Pognan, N; Quinlan, M; Rahmanzadeh, G; You, B | 1 |
| Newman, EM; Rowland, A | 1 |
| Albadry, M; Böttcher, M; Christ, B; Christ, M; Dahmen, U; Dirsch, O; Ehteshamzad, N; Höpfl, S; Klopfleisch, R; König, M; Laue, H; Lupp, A; Neumann, J; Radde, N; Schwen, LO | 1 |
| Chen, SY; Chen, Y; Gong, ZP; Huang, J; Huang, Y; Li, Y; Li, YT; Wang, YL; Yang, HL; Zheng, L | 1 |
| Bansal, S; Paine, MF; Spindle, TR; Thummel, KE; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA | 1 |
| Ah-See, ML; Edenfield, WJ; Lewis, LD; Li, Y; Mugundu, GM; Nadeau, L; Någård, M; Ottesen, LH; Safran, HP; Strauss, J; Wise-Draper, T | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
4 review(s) available for midazolam and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Topics: Administration, Oral; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Clinical Trials as Topic; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Midazolam; Mixed Function Oxygenases; Modafinil; Pharmaceutical Preparations; Theophylline | 2008 |
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Topics: Adult; Biological Availability; Caffeine; Case-Control Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytokines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Models, Biological; Patient Acuity; Psoriasis; Warfarin; Young Adult | 2021 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
49 trial(s) available for midazolam and caffeine
| Article | Year |
|---|---|
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Topics: Adult; Anti-Anxiety Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Benzenesulfonates; Caffeine; Central Nervous System Stimulants; Cimetidine; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Double-Blind Method; Histamine H2 Antagonists; Humans; In Vitro Techniques; Male; Methylation; Microsomes, Liver; Midazolam; Oxidoreductases, N-Demethylating; Psychomotor Performance; Ranitidine; Thiazoles | 1999 |
Flumazenil discrimination by humans under a two-response and a novel-response procedure.
Topics: Adolescent; Adult; Caffeine; Central Nervous System Stimulants; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Flumazenil; GABA Modulators; Humans; Male; Midazolam; Psychomotor Performance; Triazolam | 1999 |
Midazolam 12 mg is moderately counteracted by 250 mg caffeine in man.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Flicker Fusion; Humans; Hypnotics and Sedatives; Male; Midazolam; Placebos; Psychomotor Performance | 2000 |
The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dietary Supplements; Drug Interactions; Enzyme Induction; Female; Humans; Hypericum; Injections, Intravenous; Isoenzymes; Male; Midazolam; Oxidoreductases, N-Demethylating; Plant Extracts; Tolbutamide | 2001 |
An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cross-Over Studies; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; Diclofenac; Drug Interactions; Female; Humans; Male; Mephenytoin; Midazolam; Muscle Relaxants, Central; Oxidoreductases, N-Demethylating | 2001 |
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase | 2003 |
Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
Topics: Adult; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Debrisoquin; Drug Combinations; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Plasma; Tolbutamide | 2004 |
In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.
Topics: Adrenergic Agents; Adult; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Citrus; Cytochrome P-450 Enzyme System; Debrisoquin; Dietary Supplements; Drug Interactions; Echinacea; Female; GABA Modulators; Humans; Isoenzymes; Kinetics; Male; Midazolam; Phenotype; Plant Extracts; Serenoa; Silybum marianum; Solubility | 2004 |
In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Capsules; Cimicifuga; Dietary Supplements; Drug Administration Schedule; Female; Herb-Drug Interactions; Humans; Hydrastis; Kava; Male; Midazolam; Patient Selection; Phenotype; Time Factors; Valerian | 2005 |
Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba.
Topics: Administration, Oral; Aged; Allyl Compounds; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dietary Supplements; Drug Administration Schedule; Female; Ginkgo biloba; Herb-Drug Interactions; Humans; Hypericum; Isoenzymes; Male; Midazolam; Panax; Phenotype; Plant Preparations; Sulfides | 2005 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase | 2005 |
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; CCR5 Receptor Antagonists; Dextromethorphan; Diketopiperazines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Omeprazole; Piperazines; Spiro Compounds; Warfarin | 2006 |
Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Genotype; Humans; Isoenzymes; Linear Models; Losartan; Male; Midazolam; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymerase Chain Reaction; Reference Values; Time Factors | 2007 |
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Caffeine; Chlorzoxazone; Coumarins; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Mephenytoin; Metoprolol; Midazolam; Middle Aged | 2007 |
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Fluvoxamine; Genotype; Humans; Male; Midazolam; Middle Aged; Phenotype; Polymorphism, Genetic; Substrate Specificity; Switzerland; Young Adult | 2009 |
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Warfarin; Young Adult | 2009 |
Repeated administration of berberine inhibits cytochromes P450 in humans.
Topics: Adult; Berberine; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Drug Interactions; Drugs, Chinese Herbal; Enzyme Inhibitors; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2012 |
Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Topics: Adolescent; Adult; Anticonvulsants; Area Under Curve; Benzodiazepines; Caffeine; Central Nervous System Stimulants; Clinical Trials, Phase I as Topic; Clobazam; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Hypoglycemic Agents; Isoenzymes; Lamotrigine; Male; Midazolam; Middle Aged; Models, Statistical; Pharmacokinetics; Prospective Studies; Tolbutamide; Triazines; Valproic Acid; Young Adult | 2012 |
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biotransformation; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Dextromethorphan; Diuretics; Excitatory Amino Acid Antagonists; Female; Furosemide; GABA Modulators; Gastric Bypass; Humans; Hypoglycemic Agents; Male; Midazolam; Middle Aged; Omeprazole; Pharmacokinetics; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2013 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.
Topics: Caffeine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dietary Supplements; Female; Herb-Drug Interactions; Humans; Male; Midazolam; Plant Extracts; Silybin; Silybum marianum; Silymarin; Tolbutamide; Young Adult | 2014 |
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult | 2015 |
Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Topics: Adult; Area Under Curve; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Lisdexamfetamine Dimesylate; Male; Midazolam; Omeprazole | 2015 |
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Warfarin; Young Adult | 2015 |
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Topics: Adult; Alkynes; Benzoxazines; Caffeine; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Genotype; Humans; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Phenotype; Young Adult | 2016 |
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
Topics: Bayes Theorem; Caffeine; Computer Simulation; Dextromethorphan; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Phenotype; Pilot Projects; Tolbutamide | 2016 |
Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
Topics: Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Plant Extracts; Rhodiola; Young Adult | 2016 |
Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Topics: Adolescent; Adult; Bupropion; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Drug Interactions; Female; Flurbiprofen; Genotyping Techniques; Humans; Male; Midazolam; Omeprazole; Phenotype; Terfenadine; Young Adult | 2016 |
The CYTONOX trial.
Topics: Adolescent; Caffeine; Child; Chlorzoxazone; Clinical Protocols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Denmark; Female; Humans; Male; Midazolam; Pediatric Obesity | 2016 |
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Imidazoles; Male; Midazolam; Middle Aged; Omeprazole; Pituitary ACTH Hypersecretion; Pyridines | 2017 |
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult | 2017 |
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Dried Blood Spot Testing; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Models, Biological; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Prospective Studies; Protein Kinase Inhibitors; Substrate Specificity; Tandem Mass Spectrometry; Treatment Outcome | 2017 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Caffeine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Tandem Mass Spectrometry; Warfarin | 2018 |
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin | 2018 |
Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
Topics: Adult; Area Under Curve; Caffeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Losartan; Male; Midazolam; Modafinil; Omeprazole; Phenotype; Time Factors; Young Adult | 2018 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Injections, Subcutaneous; Interleukin-23 Subunit p19; Male; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Treatment Outcome; Warfarin; Young Adult | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Midazolam; Omeprazole; Psoriasis; Severity of Illness Index; Substrate Specificity; Warfarin | 2019 |
Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
Topics: Adult; Biomarkers; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Diet; Genotype; Humans; Male; Midazolam; Phenotype; Racial Groups; Rifampin; Uric Acid; Young Adult | 2019 |
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Midazolam; Middle Aged; Omeprazole; Phenotype; Vitamin K; Warfarin | 2020 |
Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Topics: Administration, Intravenous; Administration, Oral; Alfentanil; Anti-Bacterial Agents; Caffeine; Computer Simulation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Female; Gentamicins; Gestational Age; Humans; Hypnotics and Sedatives; Ibuprofen; Infant, Newborn; Kidney; Liver; Male; Metabolic Clearance Rate; Midazolam; Models, Biological; Narcotics; Predictive Value of Tests; Premature Birth; Vancomycin | 2020 |
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Warfarin; Young Adult | 2020 |
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Biotransformation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Midazolam; Models, Theoretical; Patient Safety; Purines; Rifampin; Risk Assessment; Ritonavir | 2020 |
Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Topics: Administration, Oral; Adult; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Male; Midazolam; Models, Biological; Omeprazole; Young Adult | 2021 |
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Bupropion; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Gene Expression Regulation; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Naphthoquinones; Neoplasm Proteins; Omeprazole; Rosuvastatin Calcium; Young Adult | 2021 |
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Female; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Porphyrias, Hepatic; Pyrrolidines; RNA, Small Interfering | 2021 |
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Topics: Caffeine; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Tolbutamide | 2022 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Middle Aged; Neoplasms; Omeprazole | 2023 |
91 other study(ies) available for midazolam and caffeine
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Topics: Animals; Biological Availability; Dogs; Humans; Least-Squares Analysis; Liver; Multivariate Analysis; Neural Networks, Computer; Pharmacokinetics; Rats | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis.
Topics: Animals; Antifungal Agents; Blood-Brain Barrier; Brain; Carbolines; Colony Count, Microbial; Cryptococcus neoformans; DNA Breaks, Double-Stranded; Drug Discovery; Humans; Meningitis, Cryptococcal; Mice; Microbial Sensitivity Tests; Structure-Activity Relationship | 2019 |
Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam.
Topics: Animals; Caffeine; Discrimination Learning; Drug Synergism; Male; Midazolam; Panic Disorder; Psychomotor Performance; Rats; Receptors, GABA-A | 1991 |
Synergism by caffeine and by cocaine of the motor control deficit produced by midazolam.
Topics: Animals; Caffeine; Cocaine; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Synergism; Male; Midazolam; Psychomotor Performance; Rats | 1991 |
Discriminative-stimulus effects of midazolam in squirrel monkeys: comparison with other drugs and antagonism by Ro 15-1788.
Topics: Animals; Azabicyclo Compounds; Barbital; Benzodiazepines; Benzodiazepinones; Buspirone; Caffeine; Chlordiazepoxide; Cinanserin; Clozapine; Conditioning, Operant; Cyproheptadine; Diazepam; Diphenhydramine; Discrimination Learning; Electroshock; Flumazenil; Male; Midazolam; Muscimol; Nordazepam; Pentobarbital; Piperazines; Pyridazines; Pyrimidines; Saimiri; Tripelennamine | 1985 |
GABA-induced depolarizing responses of the frog spinal cord can be either enhanced or antagonized by the benzodiazepine midazolam and the methylxanthine caffeine.
Topics: Animals; Benzodiazepines; Caffeine; Culture Techniques; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Midazolam; Neural Inhibition; Ranidae; Receptors, Cell Surface; Receptors, GABA-A; Spinal Cord; Stimulation, Chemical; Synaptic Transmission | 1984 |
Caffeine-induced hypodipsia in water-deprived rats: relationships with benzodiazepine mechanisms.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Caffeine; Diazepam; Drinking Behavior; Male; Midazolam; Rats; Satiation; Time Factors; Water Deprivation | 1982 |
Effects of midazolam on directly stimulated muscle biopsies from control and malignant hyperthermia positive patients.
Topics: Anti-Anxiety Agents; Benzodiazepines; Caffeine; Halothane; Humans; In Vitro Techniques; Malignant Hyperthermia; Midazolam; Muscle Contraction; Muscles; Preanesthetic Medication | 1984 |
Influence of caffeine and midazolam on gamma-aminobutyric acid-evoked responses in the frog spinal cord.
Topics: Animals; Benzodiazepines; Caffeine; Drug Synergism; Electrophysiology; gamma-Aminobutyric Acid; In Vitro Techniques; Midazolam; Rana temporaria; Receptors, Cell Surface; Receptors, GABA-A; Spinal Cord | 1983 |
Grapefruit juice interactions with drugs.
Topics: Beverages; Caffeine; Citrus; Cyclosporine; Estrogens; Felodipine; Food-Drug Interactions; Humans; Midazolam; Nifedipine; Terfenadine | 1995 |
Drug discrimination analysis of midazolam under a three-lever procedure: I. Dose-dependent differences in generalization and antagonism.
Topics: Animals; Caffeine; Cocaine; Dextroamphetamine; Discrimination Learning; Dose-Response Relationship, Drug; Flumazenil; Male; Methocarbamol; Midazolam; Morphine; Pentobarbital; Rats; Rats, Sprague-Dawley | 1995 |
Tolerance to the behavioral effects of chlordiazepoxide: pharmacological and biochemical selectivity.
Topics: Amphetamine; Animals; Behavior, Animal; Caffeine; Carbolines; Chlordiazepoxide; Chlorides; Chlorine; Dose-Response Relationship, Drug; Drug Tolerance; Flumazenil; gamma-Aminobutyric Acid; Male; Midazolam; Morphine; Pentobarbital; Radioisotopes; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Sensitivity and Specificity; Stimulation, Chemical | 1993 |
Effects of midazolam on contractions in smooth muscle of the rabbit mesenteric artery.
Topics: Adrenergic alpha-Agonists; Anesthetics, Intravenous; Animals; Caffeine; Calcium Channel Blockers; Dose-Response Relationship, Drug; Hypnotics and Sedatives; In Vitro Techniques; Male; Mesenteric Arteries; Midazolam; Muscle Contraction; Muscle, Smooth, Vascular; Nifedipine; Norepinephrine; Potassium; Rabbits | 1997 |
Possible mechanisms underlying the midazolam-induced relaxation of the noradrenaline-contraction in rabbit mesenteric resistance artery.
Topics: Animals; Caffeine; Calcium; Calcium Channel Blockers; In Vitro Techniques; Male; Membrane Potentials; Mesenteric Arteries; Midazolam; Muscle Contraction; Muscle Relaxation; Nicardipine; Norepinephrine; Potassium; Rabbits; Vascular Resistance; Vasodilator Agents | 1997 |
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
Topics: Acetyltransferases; Adult; Anti-Anxiety Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Female; Fluvoxamine; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Oxidoreductases, N-Demethylating; Phenotype; Reference Values; Selective Serotonin Reuptake Inhibitors; Time Factors; Xanthine Oxidase | 1998 |
AND and AND-OR drug mixture discriminations in rats: generalization to single drugs and drug mixtures.
Topics: Animals; Anti-Anxiety Agents; Caffeine; Central Nervous System Depressants; Central Nervous System Stimulants; Cocaine; Dextroamphetamine; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Ethanol; Generalization, Response; Male; Midazolam; Nicotine; Nicotinic Agonists; Rats | 1999 |
Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry.
Topics: Automation; Caffeine; Chlorzoxazone; Chromatography, Gas; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debrisoquin; Diclofenac; Glucuronidase; Humans; Indicators and Reagents; Midazolam; Reproducibility of Results; Sensitivity and Specificity; Substrate Specificity; Theophylline | 1999 |
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Polymerase Chain Reaction; Xanthine Oxidase | 2000 |
Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Caffeine; China; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Isoenzymes; Male; Mephenytoin; Metoprolol; Midazolam; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Phenotype; Reference Values; Theophylline | 2003 |
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Topics: Administration, Oral; Adult; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Echinacea; Female; Herb-Drug Interactions; Humans; Infusions, Intravenous; Male; Midazolam; Phytotherapy; Plant Extracts; Plant Roots; Reference Values; Tolbutamide | 2004 |
A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.
Topics: Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Flurbiprofen; Humans; Isoenzymes; Midazolam; Omeprazole; Phenotype; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Oral and intravenous caffeine for treatment of children with post-sedation paradoxical hyperactivity.
Topics: Administration, Oral; Adolescent; Anesthetics, Intravenous; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Child; Child, Preschool; Female; Fentanyl; Humans; Hypnotics and Sedatives; Infant; Injections, Intravenous; Male; Midazolam; Pentobarbital; Psychomotor Agitation; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
Topics: Algorithms; Caffeine; Carbamazepine; Child; Computer Simulation; Humans; Infant; Infant, Newborn; Metabolic Clearance Rate; Midazolam; Models, Biological; Monte Carlo Method; Software | 2006 |
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Carbamazepine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Digoxin; Enzyme Induction; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Substrate Specificity | 2008 |
Caffeine poisoning and lactate rise: an overlooked toxic effect?
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antidotes; Anxiety; Caffeine; Central Nervous System Stimulants; Charcoal; Female; Gastric Lavage; Humans; Hypokalemia; Lactic Acid; Midazolam; Ondansetron; Propranolol; Rare Diseases; Severity of Illness Index; Suicide, Attempted; Treatment Outcome | 2008 |
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Dextrorphan; Female; Humans; Isomerism; Male; Methadone; Midazolam; Middle Aged; Narcotics; Opioid-Related Disorders; Saliva; Young Adult | 2009 |
A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients.
Topics: Biotransformation; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Midazolam; Omeprazole; Phenotype; Tandem Mass Spectrometry | 2009 |
Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.
Topics: Adult; Angelica; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Dextromethorphan; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Phytotherapy; Republic of Korea; Scutellaria baicalensis; Tandem Mass Spectrometry; Young Adult | 2009 |
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Humans; Hydrazines; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Pyrazoles; Receptors, Thrombopoietin | 2010 |
Variability in drug metabolizing enzyme activity in HIV-infected patients.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; HIV Infections; Humans; Interleukin-6; Male; Midazolam; Phenotype; Tumor Necrosis Factor-alpha; Xanthine Oxidase | 2010 |
Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping.
Topics: Adult; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; Genotype; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Phenotype; Pilot Projects; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2012 |
Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.
Topics: Animals; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drugs, Chinese Herbal; Enzyme Inhibitors; Erigeron; Herb-Drug Interactions; Metoprolol; Midazolam; Rats; Rats, Sprague-Dawley; Tolbutamide | 2012 |
A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Area Under Curve; Blotting, Western; Caffeine; Cells, Cultured; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Drug Interactions; GABA Modulators; Hepatocytes; Heterocyclic Compounds, 2-Ring; Humans; Male; Midazolam; Middle Aged; Receptors, GABA-A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2012 |
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Design; Female; Humans; Metoprolol; Midazolam; Models, Biological; Pregnancy; Pregnancy Trimester, Third; Young Adult | 2012 |
Predicted metabolic drug clearance with increasing adult age.
Topics: Adult; Aged; Aged, 80 and over; Aging; Caffeine; Computer Simulation; Desipramine; Female; Humans; Male; Mephenytoin; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Warfarin | 2013 |
Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Brassica; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochromes; Dextromethorphan; Enzyme Inhibitors; Herb-Drug Interactions; Liver; Metabolic Clearance Rate; Midazolam; Omeprazole; Rats; RNA, Messenger; Tolbutamide | 2012 |
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin | 2012 |
Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.
Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Activation; Female; Ischemic Preconditioning; Isoenzymes; Liver; Male; Metoprolol; Midazolam; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Tolbutamide | 2014 |
The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro.
Topics: Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Humans; In Vitro Techniques; Kinetics; Midazolam; Organic Chemicals; Solvents | 2013 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?
Topics: Adult; Area Under Curve; Biomedical Research; Caffeine; Child; Child, Preschool; Female; Humans; Ibuprofen; Infant; Infant, Newborn; Itraconazole; Male; Midazolam; Models, Biological; Pharmacokinetics; Sample Size; Theophylline | 2014 |
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley | 2014 |
Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Flurbiprofen; Half-Life; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2014 |
A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data.
Topics: Adolescent; Adult; Age Factors; Alfentanil; Amides; Caffeine; Child; Child, Preschool; Computer Simulation; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Metabolic Clearance Rate; Midazolam; Models, Biological; Ropivacaine; Theophylline | 2014 |
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Capsules; Carbonated Beverages; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Coffee; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Enzyme Inhibitors; Feasibility Studies; Flurbiprofen; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Pilot Projects; Predictive Value of Tests; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2014 |
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin | 2015 |
Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
Topics: Animals; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Liver; Male; Midazolam; Omeprazole; Plant Extracts; Polygonum; Rats; Rats, Sprague-Dawley; Tolbutamide | 2014 |
Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Topics: Administration, Intravenous; Administration, Oral; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Biological; Omeprazole; Pharmacokinetics; Warfarin | 2015 |
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin | 2016 |
Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Topics: Animals; Caffeine; Chimera; Cytochrome P-450 Enzyme System; Dogs; Humans; Macaca fascicularis; Mice; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations; Pharmacokinetics; Swine; Swine, Miniature; Warfarin | 2016 |
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
Topics: Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Interleukin-6; Midazolam | 2016 |
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin | 2016 |
Identification of Drugs in Parenteral Pharmaceutical Preparations from a Quality Assurance and a Diversion Program by Direct Analysis in Real-Time AccuTOFTM-Mass Spectrometry (DART-MS).
Topics: Amides; Analgesics; Anesthetics; Baclofen; Bupivacaine; Caffeine; Chromatography, High Pressure Liquid; Clonidine; Dexamethasone; Ephedrine; Fentanyl; Heparin; Hydromorphone; Ketamine; Mass Spectrometry; Methadone; Midazolam; Morphine; Oxytocin; Parenteral Nutrition Solutions; Phenylephrine; Ropivacaine; Succinylcholine | 2016 |
Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Fermented Foods; Healthy Volunteers; Humans; Losartan; Male; Midazolam; Middle Aged; Omeprazole; Panax; Pharmaceutical Preparations; Terfenadine; Young Adult | 2016 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Topics: Caffeine; Cytochrome P-450 Enzyme System; Diazepam; Female; Granisetron; Humans; Metoprolol; Metronidazole; Midazolam; Models, Biological; Nifedipine; Ondansetron; Pharmaceutical Preparations; Pregnancy | 2018 |
Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P450 Family 2; Drugs, Chinese Herbal; Enzyme Activation; Herb-Drug Interactions; Isoenzymes; Midazolam; Omeprazole; Rats; Steroid 16-alpha-Hydroxylase; Tolbutamide; Warfarin | 2017 |
Development of a simultaneous LC-MS/MS method to predict in vivo drug-drug interaction in mice.
Topics: Animals; Caffeine; Chromatography, Liquid; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Dextromethorphan; Drug Interactions; Forecasting; Male; Mice; Mice, Inbred ICR; Midazolam; Tandem Mass Spectrometry | 2018 |
A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Liver-Specific Organic Anion Transporter 1; Losartan; Male; Midazolam; Omeprazole; Panax; Plant Preparations; Random Allocation; Young Adult | 2018 |
LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Variation, Population; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Healthy Volunteers; Humans; Isoenzymes; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Terfenadine | 2019 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Bupropion; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diabetes Mellitus, Type 2; Female; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Tolbutamide; Tumor Necrosis Factor-alpha | 2019 |
An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.
Topics: Biosensing Techniques; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Limit of Detection; Losartan; Midazolam; Omeprazole; Phenotype; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Topics: Administration, Oral; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Esomeprazole; Female; Healthy Volunteers; Humans; Male; Midazolam; Models, Biological; Pantoprazole; Pharmacogenomic Variants | 2020 |
Assessing cytochrome P450-based drug-drug interactions with hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats.
Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Interactions; Hemoglobins; Liposomes; Male; Midazolam; Rats; Rats, Sprague-Dawley; Tolbutamide | 2020 |
Evaluation of cytochrome P450-based drug metabolism in hemorrhagic shock rats that were transfused with native and an artificial red blood cell preparation, Hemoglobin-vesicles.
Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Interactions; Hemoglobins; Liposomes; Male; Midazolam; Rats; Rats, Sprague-Dawley; Shock, Hemorrhagic; Tolbutamide | 2020 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Flurbiprofen; Humans; Liver Cirrhosis; Metoprolol; Midazolam; Omeprazole | 2022 |
Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.
Topics: Area Under Curve; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam | 2023 |
Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme System; Fatty Liver; Metabolic Clearance Rate; Mice; Midazolam | 2022 |
[Effect of Laportea bulbifera extract on CYP450 enzyme activities in rats by Cocktail probe drug method].
Topics: Animals; Caffeine; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Metoprolol; Midazolam; Omeprazole; Plant Extracts; Rats; Tandem Mass Spectrometry; Tolbutamide | 2022 |
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Topics: Adult; Caffeine; Cannabidiol; Cannabinoids; Cannabis; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dronabinol; Drug Interactions; Hallucinogens; Humans; Losartan; Midazolam; Omeprazole; Plant Extracts | 2023 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |